478 related articles for article (PubMed ID: 9769897)
21. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
22. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
23. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
Henry SP; Geary RS; Yu R; Levin AA
Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
[TBL] [Abstract][Full Text] [Related]
24. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
25. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
26. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
Mirabelli CK; Bennett CF; Anderson K; Crooke ST
Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and clinical experience of antisense therapy for solid tumors.
Webb MS; Zon G
Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
[TBL] [Abstract][Full Text] [Related]
29. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
31. Antisense tumor therapy (a dream under construction).
Kopper L; Kovalszky I
In Vivo; 1994; 8(5):781-6. PubMed ID: 7727725
[TBL] [Abstract][Full Text] [Related]
32. [Synthetic oligonucleotides and their application in gene therapy].
Iribarren AM
Medicina (B Aires); 1995; 55(3):263-6. PubMed ID: 8544726
[TBL] [Abstract][Full Text] [Related]
33. Application of antisense oligonucleotides for gene functionalization and target validation.
Bennett CF; Cowsert LM
Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
[TBL] [Abstract][Full Text] [Related]
34. Technology evaluation: MG-98, MethylGene.
Zhang Z
Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
[TBL] [Abstract][Full Text] [Related]
35. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotide derivatives as gene-targeted drugs.
Knorre DG; Vlassov VV
Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
[TBL] [Abstract][Full Text] [Related]
37. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
38. The role of antisense oligonucleotides in the treatment of bladder cancer.
Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
[TBL] [Abstract][Full Text] [Related]
39. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
Orum H; Wengel J
Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
[TBL] [Abstract][Full Text] [Related]
40. Oligonucleotides--from design to the clinic.
Bennett CF
Curr Opin Mol Ther; 1999 Jun; 1(3):296. PubMed ID: 11713793
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
